Table 1.
Baseline characteristics of RA patients included in the discovery study
| Characteristic | Good-responders (n = 50) | Non-responders (n = 20) | p value |
|---|---|---|---|
| Age, mean (SD) | 58.1 (13.1) | 55.3 (13) | 0.42a |
| Female, n (%) | 31 (62) | 15 (75) | 0.30b |
| Days on drug at outcome, median (IQR) | 113 (92, 147) | 109 (93, 147) | 0.74c |
| Baseline DAS28, mean (SD) | 5.07 (0.90) | 5.09 (0.90) | 0.93a |
| Concurrent DMARD therapy, n (%) | 46 (92) | 15 (75) | 0.06b |
| Swollen joint count, median (IQR) | 8 (5, 11) | 6 (3, 8) | 0.13c |
| Tender joint count, median (IQR) | 12 (6, 17) | 17 (9, 23) | 0.15c |
| Baseline HAQ score, median (IQR) | 1.5 (1, 2.13) | 1.8 (1.4, 2.3) | 0.21c |
Patients were stratified by EULAR response at 3 months. All patients receiving concurrent DMARD therapy were receiving methotrexate. DAS28 28-joint count disease activity score, DMARD disease modifying anti-rheumatic drugs, HAQ health assessment questionnaire, SD standard deviation, IQR interquartile range. p value: atwo-sample t test, bchi-squared test, cWilcoxon rank-sum test